PROVENTIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROVENTIL (PROVENTIL).
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP
| Metabolism | Primarily hepatic via conjugation to inactive metabolites; not metabolized by CYP450 enzymes |
| Excretion | Renal: ~90% (mostly as sulfate conjugates after oral administration, unchanged drug after inhalation); biliary/fecal: <10%. |
| Half-life | Terminal elimination half-life: 3.8–6 hours (inhalation), 3.7–7.1 hours (oral); clinical context: supports dosing every 4–6 hours as needed. |
| Protein binding | ~10% bound; primarily to unspecified plasma proteins (low binding). |
| Volume of Distribution | Inhalation: ~2.0 L/kg; oral: ~2.5 L/kg. Vd suggests extensive distribution into tissues. |
| Bioavailability | Inhalation: 10–20% (lung deposition); oral: ~50% (first-pass metabolism reduces systemic availability; actual therapeutic effect requires direct airway delivery). |
| Onset of Action | Inhalation: 5–15 minutes; oral: 15–30 minutes. |
| Duration of Action | Inhalation: 3–6 hours (bronchodilation); oral: 4–8 hours. Tolerance may develop with regular use. |
Inhalation: 2 inhalations (90 mcg each) every 4-6 hours as needed; oral: 2-4 mg three to four times daily; extended-release: 4-8 mg every 12 hours.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, use with caution and consider dose reduction due to potential accumulation. |
| Liver impairment | Child-Pugh Class A: No adjustment; Class B: Reduce dose by 50%; Class C: Avoid use or use with extreme caution. |
| Pediatric use | Inhalation: 1-2 inhalations (90 mcg each) every 4-6 hours as needed for children ≥4 years; oral: 0.1-0.2 mg/kg/dose three times daily (max 4 mg/dose) for children 2-12 years; for <2 years, safety not established. |
| Geriatric use | Use lower initial doses due to increased sensitivity; inhalation: 1-2 inhalations every 4-6 hours; oral: 2 mg three to four times daily initially, titrate cautiously. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROVENTIL (PROVENTIL).
| Breastfeeding | Albuterol is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 2.5, but absolute infant doses are low (<2% of maternal weight-adjusted dose). Inhaled albuterol results in minimal systemic absorption, thus levels in milk are negligible. No adverse effects in breastfed infants have been reported. It is considered compatible with breastfeeding. |
| Teratogenic Risk | Albuterol (PROVENTIL) is generally considered low risk for major congenital malformations. Inhaled beta-agonists do not appear to be major teratogens. However, high-dose systemic administration (oral or IV) in animal studies has shown some adverse effects, but data in humans are limited. First trimester exposure does not significantly increase risk of major birth defects. Third trimester use may cause transient maternal and fetal tachycardia, but no structural anomalies. Overall, the benefit of controlling asthma typically outweighs theoretical risks. |
■ FDA Black Box Warning
None
| Common Effects | Injection site pain Injection site swelling Red spots or bumps Rash |
| Serious Effects |
["History of hypersensitivity to albuterol or any component of the formulation"]
| Precautions | ["Paradoxical bronchospasm may occur","Cardiovascular effects (tachycardia, arrhythmias, hypertension)","Hypersensitivity reactions including anaphylaxis","Immediate hypersensitivity reactions","Use with caution in patients with cardiovascular disorders","Diabetes: may increase blood glucose","Hypokalemia may occur"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate and blood pressure, especially in high-dose or intravenous therapy. Fetal heart rate monitoring may be considered if maternal tachycardia is significant. In asthmatic patients, monitor peak expiratory flow (PEF) and symptom control. Ultrasound for fetal growth if prolonged high-dose use. No specific additional fetal monitoring required for standard inhaled use. |
| Fertility Effects | Albuterol has no known direct effects on human fertility. There are no reports of impaired fertility in males or females. Animal studies show no adverse effects on fertility at clinically relevant doses. Asthma control itself is important for fertility and pregnancy outcomes, and albuterol use does not negatively impact reproductive capacity. |